作者: Mayank Goyal , Mohammed A. Almekhlafi , Liqiong Fan , Bijoy K. Menon , Andrew M. Demchuk
DOI: 10.1161/CIRCULATIONAHA.113.007826
关键词: Medicine 、 Endovascular therapy 、 Stroke 、 Emergency medicine 、 Surgery 、 Fibrinolytic agent 、 Tissue plasminogen activator 、 Interventional management 、 Infarction 、 In patient 、 Thrombosis
摘要: Background—Meaningful delays occurred in the Interventional Management of Stroke (IMS) III trial. Analysis work flow will identify factors contributing to in-hospital delays. Methods and...